Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 27, 2015updated 01 Nov 2021 7:23am

Sinocare agrees to buy Nipro Diagnostics for $273m

China-based Sinocare Group has signed an agreement with Japan's Nipro to buy its US wholly owned subsidiary Nipro Diagnostics for $273m.

China-based Sinocare Group has signed an agreement with Japan’s Nipro to buy its US wholly owned subsidiary Nipro Diagnostics for $273m.

Based in Fort Lauderdale, Florida, Nipro Diagnostics is focused on developing, manufacturing and commercialising advanced performance products for people with diabetes, including a broad portfolio of blood glucose monitoring supplies and technologies.

The manufacturing facilities of the company are situated in Florida, New Hampshire and Taiwan.

Under the deal, Nipro will continue to buy certain products in agreed markets from Sinocare Group.

Nipro Diagnostics president Scott Verner said: “This transaction combines one of the fastest growing blood glucose monitoring companies in the US with the fastest growing blood glucose monitoring company in China.

“We have a shared vision and a singular focus to provide innovative and affordable solutions so patients can live healthier lives.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
“We will continue to innovate in our products and services and improve the quality of life for people with diabetes.”

“Together, we will offer a strong portfolio of solutions to our global customers.”

The transaction, which is subject to the satisfaction of certain conditions, is expected to be completed within ninety days.

Sinocare Group chairman Shaobo Li said: “Diabetes has become one of the biggest challenges to our public healthcare system and society.

“We welcome Nipro Diagnostics to this joint effort with Sinocare Group.

“We will continue to innovate in our products and services and improve the quality of life for people with diabetes.”

Established in 2002, Sinocare Group consists of Sinocare and its affiliates, and markets blood glucose monitoring systems in the Chinese market.

Sinocare is dedicated to innovating biosensor technology and promoting diabetic self-management by using blood glucose monitoring systems in China.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU